Ruxotemitide, formerly known as LTX-315, is an amphipathic cationic peptide potentially for the treatment of melanoma, breast cancer, head and neck cancer and lymphoma. Ruxotemitide has been shown to be inefficient in stimulating mitophagy and may trigger unregulated necrosis. References: Zhou H, Forveille S, Sauvat A, Sica V, Izzo V, Durand S, Müller K, Liu P, Zitvogel L, Rekdal O, Kepp O, Kroemer G. The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization. Oncotarget. 2015 Sep 29;6(29):26599-614. doi: 10.18632/oncotarget.5613. PubMed PMID: 26378049; PubMed Central PMCID: PMC4694939.

纯度：≥98%

CAS：1345407-05-7